Nexpowder Endoscopic Hemostasis System Cleared
Medtronic’s Nexpowder endoscopic hemostasis system has received clearance from the FDA for treating patients with upper gastrointestinal nonvariceal bleeding.
The powder is sprayed through a catheter that has a propriety powder-coating technology that minimizes clogging while improving visibility and control.
Nexpowder forms a durable gel upon contact, with or without the presence of blood, which then degrades in one to three days, the company said.
Medtronic distributes the system as part of a global supply agreement with Korea-based Next Biomedical.